BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  McCann Health Global Scientific Council Hosts Special Event At UN General Assembly Focused On Driving the Scientific Agenda Forward in A Complex Changing World

  McCann Health’s Grand Challenges in Healthcare Communications announced

  September 27, 2018

   · 

  3 min read
• Biotech Bay

  Veracyte to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 1:05 p.m. Eastern Time (ET).

  September 27, 2018

   · 

  1 min read
• Deals

  Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock

  Aldeyra Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $13.75 per share.

  September 27, 2018

   · 

  4 min read
• FDA

  Lilly’s Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

  Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous injection.1

  September 27, 2018

   · 

  13 min read